Peter Andrew Crosby

Cardiac has developed RHYTHMx ECD, technology that continuously monitors a patient's heart rhythm and provided defibrillation to help the organ keep a steady beat. Cardiac Science has used the technology to develop an external cardiac defibrillator, the Powerheart, which is used in hospitals. The firm also sold patient monitors and emergency defibrillators, and has developed a small portable defibrillator that can be used by patients in the hospital or at home. Cardiac Science markets its products in more than 50 countries worldwide.

Ventracor Ltd. manufactures and markets a range of cardiac technology products. The company has developed an implantable blood pump, the VentrAssist left ventricular assist device, designed as therapy for patients in end stage heart failure. It also engages in the research, development, manufacture, clinical trials and commercialization of the VentrAssist LVAD and related technologies. Ventracor was founded in 1986 and is headquartered in Sydney, Australia.

Mainstay Medical Ltd. operates as a medical device company which develops neuro-stimulation therapies for people with debilitating chronic low back pain. It develops ReActiv8, an active implantable medical device designed to treat people with chronic low back pain. The company was founded by Danny Sachs in 2008 and is headquartered in Dublin, Ireland.

Mainstay Medical International Ltd. is a medical device company, which is engages in the development of neurostimulation system. It focuses on the study of ReActiv8, a medical device designed to treat people with chronic low back pain. The company was founded by Danny Sachs in 2008 and is headquartered in San Diego, CA.

NeoVision Corp. manufactures surgical products. The company provides scanners, ultrasonic pulsed echo devices and other medical apparatus. It is headquartered in Norwalk, CT.

Part of Merck KGaA, First Medical, Inc. is a company that manufactures blood sample analysis equipment. The company is based in Mountain View, CA. First Medical was acquired by Sigma-Aldrich Corp., part of Merck KGaA from November 19, 2015 on July 24, 2000.

Ischemia Technologies, Inc. develops, manufactures and markets vitro diagnostic products with a focus on cardiovascular and acute care medicine. The Company was acquired by Inverness Medical Innovations, Inc. in March 2005. The company is headquartered in Denver, CO.